US20170172204A1 - Strength enhancers and method of achieving strength enhancement in an electronic vapor device - Google Patents

Strength enhancers and method of achieving strength enhancement in an electronic vapor device Download PDF

Info

Publication number
US20170172204A1
US20170172204A1 US14/974,211 US201514974211A US2017172204A1 US 20170172204 A1 US20170172204 A1 US 20170172204A1 US 201514974211 A US201514974211 A US 201514974211A US 2017172204 A1 US2017172204 A1 US 2017172204A1
Authority
US
United States
Prior art keywords
acid
vaporization formulation
oil
vaporization
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/974,211
Other languages
English (en)
Inventor
David Kane
Adam N. Anderson
Peter Lipowicz
Weiling Li
Mark RUSYNIAK
Douglas Oliveri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altria Client Services LLC
Original Assignee
Altria Client Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57749910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170172204(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altria Client Services LLC filed Critical Altria Client Services LLC
Priority to US14/974,211 priority Critical patent/US20170172204A1/en
Assigned to ALTRIA CLIENT SERVICES LLC reassignment ALTRIA CLIENT SERVICES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RUSYNIAK, Mark, LIPOWICZ, PETER, KANE, DAVID, OLIVERI, Douglas, ANDERSON, ADAM, LI, Weiling
Priority to ES16822652T priority patent/ES2749951T3/es
Priority to PL16822652T priority patent/PL3389420T3/pl
Priority to JP2018526861A priority patent/JP2019503660A/ja
Priority to CN201680068322.7A priority patent/CN108289496A/zh
Priority to RU2018125249A priority patent/RU2730706C2/ru
Priority to IL259200A priority patent/IL259200B2/en
Priority to MX2018006898A priority patent/MX2018006898A/es
Priority to EP16822652.0A priority patent/EP3389420B1/en
Priority to KR1020187015306A priority patent/KR102719796B1/ko
Priority to CA3001780A priority patent/CA3001780A1/en
Priority to PCT/EP2016/081469 priority patent/WO2017103136A1/en
Publication of US20170172204A1 publication Critical patent/US20170172204A1/en
Priority to JP2022081415A priority patent/JP2022103338A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A24F47/008—
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
    • A24B15/303—Plant extracts other than tobacco
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/34—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a carbocyclic ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/42—Treatment of tobacco products or tobacco substitutes by chemical substances by organic and inorganic substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors

Definitions

  • Example embodiments relate generally to a pre-vaporization formulation for e-vaping devices. More particularly, example embodiments relate to strength enhancers in pre-vaporization formulations.
  • Electronic vaping devices are used to vaporize a pre-vaporization formulation such as, for example, a liquid material, into a vapor in order for an adult vaper to inhale the vapor.
  • E-vaping devices typically include a heater which vaporizes the pre-vaporization formulation to produce the vapor.
  • An e-vaping device may include several e-vaping elements including a power source, a cartridge or e-vaping tank including the heater, and a reservoir holding the pre-vaporization formulation.
  • a tobacco-based smoking article produces a vapor known to create a desired sensory experience for adult smokers, including a low to moderate harshness response in the throat and a perceived warmth or strength in the chest of an adult smoker.
  • the harshness of the vapor which is typically understood as the sensation experienced in the throat of an adult vaper
  • the strength of the vapor which is typically understood as the sensation experienced in the chest of the adult vaper
  • an e-vaping device is harsher than a tobacco-based product, but has a strength that is lower than the strength of the tobacco-based product.
  • the harshness of the e-vaping device increases.
  • At least one example embodiment relates to an e-vaping device configured to achieve a desirable balance of strength and harshness, where strength is increased without increasing harshness.
  • At least one example embodiment relates to an e-vaping device that is configured to provide a perceived sensory experience for adult vapers that is similar to the sensory experience enjoyed while smoking a tobacco-based cigarette.
  • Another example embodiment relates to an e-vaping device that is configured to provide a sensory experience including levels of harshness in the throat and perceived strength or warmth in the chest that are similar to those experienced when smoking a tobacco-based product.
  • the strength of the e-vaping product may be increased without increasing the harshness thereof.
  • a pre-vaporization formulation such as, for example, a liquid formulation, of an e-vaping device includes a mixture of a vapor former, nicotine, one or more strength enhancers or additives, and optionally water and/or one or more acids.
  • the strength enhancers or additives may include cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • the strength enhancers may also include capsicum , allyl isothiocyanate, piperine, isoeugenol, carvacrol, thymol, menthol, monomenthyl succinate and N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropyl butanamide.
  • the strength enhancers include one or more compounds that activate receptors in the respiratory system of an adult vaper such as the transient receptor potential cation channel, subfamily A, member 1 (TRPA1), the transient receptor potential cation channel subfamily V member 1 (TPRV1), or the nicotinic-acetylcholine receptors in an adult vaper, the agonists becoming part of the vapor and are carried in the respiratory tract of the adult vaper during vaping.
  • TRPA1 transient receptor potential cation channel, subfamily A, member 1
  • TPRV1 transient receptor potential cation channel subfamily V member 1
  • nicotinic-acetylcholine receptors in an adult vaper
  • the strength enhancer or additive may include one or more of the above-listed compounds, among others, in a composition range of about 0.0001% to about 1%, or in concentrations of up to 2%.
  • the concentration the strength enhancer may be greater than 2% when several strength enhancers are used in combination.
  • the total concentration of strength enhancers may be up to about 5%.
  • the above compounds as well as others can be found in extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • harshness reduction compounds such as acids can be included in the pre-vaporization formulation in order to achieve a desired balance of increased strength and decreased harshness in an e-vaping device.
  • the strength enhancers may be used in a pre-vaporization formulation that does not include nicotine, the strength enhancers providing a level of strength that is similar to the strength experienced by an adult vaper when vaping a nicotine-containing vaping device or a tobacco-based article.
  • strength enhancers may be included in smoke cessation inhalation devices.
  • the strength enhancers increase the strength of the e-vaping device without increasing the delivery of nicotine and without increasing the harshness of the e-vaping article.
  • a pre-vaporization formulation of an e-vaping device such as, for example, a liquid formulation, includes a mixture of a vapor former, nicotine in an amount of about 0.5% to about 2% by weight or greater, or of about 0.5% to about 5% or greater, one or more strength enhancers, one or more acids and optionally water.
  • the vapor formed by the vapor former includes a gas phase and a particulate phase, and the concentration of nicotine in the vapor phase is less than or equal to 1%.
  • the pre-vaporization formulation may include one or more acids having a boiling point of at least about 100° C. and configured to volatilize when heated by a heater in the e-vaping device.
  • the pre-vaporization formulation is configured to form a vapor having a particulate phase and a gas phase when heated by the heater in the e-vaping device, the particulate phase containing protonated nicotine and the gas phase containing unprotonated nicotine.
  • the vapor has a majority amount of the protonated nicotine and a minority amount of the unprotonated nicotine.
  • the pre-vaporization formulation is configured to form a vapor having a nicotine gas phase component upon operation of the e-vaping device.
  • the acid is included in an amount sufficient to reduce the nicotine gas phase component by about 70% or greater.
  • the addition of one or more acids may reduce the gas phase nicotine content by an amount in the range of about 40% to about 70% by weight, or in the range of about 40% to about 90% by weight.
  • the acid is selected to have a liquid to vapor transfer efficiency of about 50% or greater, and in an amount sufficient to reduce the nicotine gas phase component.
  • the vapor former may include propylene glycol and glycerol or glycerin.
  • the acidic compound includes at least one of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid, 2-methylvaleric acid, myristic acid, nonanoic acid, palmitic acid, 4-pentenoic acid, phenylacetic acid, 3-phenylpropionic acid, hydrochloric acid
  • the acidic compound includes pyruvic acid, lactic acid, benzoic acid and acetic acid.
  • the e-vaping device includes a first section and a second section.
  • the first section includes a pre-vaporization formulation reservoir including a pre-vaporization formulation such as, for example, a liquid material, a heater, a wick in communication with the pre-vaporization formulation reservoir and in communication with the heater, a mouth-end piece, and a connector at a distal end of the first section.
  • the second section includes a power supply, and a connector at a proximal end of the second section configured to matingly connect with the connector of the first section.
  • FIG. 1 is a side view of an e-vaping device, according to an example embodiment
  • FIG. 2 is a cross-sectional view of an e-vaping device, according to an example embodiment.
  • FIG. 3 is a cross-sectional view of another example embodiment of an e-vaping device.
  • first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of example embodiments.
  • spatially relative terms e.g., “beneath,” “below,” “lower,” “above,” “upper,” and the like
  • the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below” or “beneath” other elements or features would then be oriented “above” the other elements or features. Thus, the term “below” may encompass both an orientation of above and below.
  • the device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
  • Example embodiments are described herein with reference to cross-sectional illustrations that are schematic illustrations of idealized embodiments (and intermediate structures) of example embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, example embodiments should not be construed as limited to the shapes of regions illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the actual shape of a region of a device and are not intended to limit the scope of example embodiments.
  • vapor former describes any suitable known compound or mixture of compounds that, in use, facilitates formation of a vapor and that is substantially resistant to thermal degradation at the operating temperature of the e-vaping device.
  • Suitable vapor-formers consist of various compounds such as, for example, polyhydric alcohols including propylene glycol and/or glycerol or glycerin.
  • the vapor former is propylene glycol.
  • FIG. 1 is a side view of an e-vaping device 60 , according to an example embodiment.
  • the e-vaping device 60 includes a first section or cartomizer 70 and a second section 72 , which are coupled together at a threaded joint 74 or by other connecting structure such as a snug-fit, snap-fit, detent, clamp and/or clasp or the like.
  • the first section or cartomizer 70 may be a replaceable cartridge and the second section 72 may be a reusable section.
  • the first section or cartomizer 70 and the second section 72 may be integrally formed in one piece.
  • FIG. 2 is a cross-sectional view of an example embodiment of an e-vaping device.
  • the first section or cartomizer 70 can house a mouth-end insert 20 , a capillary vapor generator including a capillary tube 18 , a heater 19 to heat at least a portion of the capillary tube 18 , and a reservoir 14 .
  • the second section 72 can house a power supply 12 , a control circuitry 11 configured to control the power supply 12 , and a puff sensor 16 .
  • the puff sensor is configured to sense when an adult vaper is puffing on the e-vaping device 60 , which triggers operation of the power supply 12 via the control circuitry 11 to activate the heater 19 to heat the pre-vaporization formulation housed in the reservoir 14 and form a vapor.
  • a threaded portion 74 of the second section 72 can be connected to a battery charger, when not connected to the first section or cartomizer 70 , to charge the battery or power supply 12 .
  • a valve 40 can be a two-way valve, and the reservoir 14 can be pressurized.
  • the reservoir 14 can be pressurized using a pressurization arrangement 405 configured to apply constant pressure to the reservoir 14 . As such, emission of vapor formed via heating of the pre-vaporization formulation housed in the reservoir 14 is facilitated.
  • the capillary tube 18 is formed of or includes a conductive material, and thus acts as its own heater 19 by passing current through the tube.
  • the capillary tube 18 may be any electrically conductive material capable of being resistively heated, while retaining the necessary structural integrity at the operating temperatures experienced by the capillary tube 18 , and which is non-reactive with the pre-vaporization formulation.
  • Suitable materials for forming the capillary tube 18 are one or more of stainless steel, copper, copper alloys, porous ceramic materials coated with film resistive material, nickel-chromium alloys, and combinations thereof.
  • the capillary tube 18 is a stainless steel capillary tube 18 and serves as a heater 19 via electrical leads 26 attached thereto for passage of direct or alternating current along a length of the capillary tube 18 .
  • the stainless steel capillary tube 18 is heated by resistance heating.
  • the capillary tube 18 may be a non-metallic tube such as, for example, a glass tube.
  • the heater 19 is formed of or includes a conductive material capable of being resistively heated, such as, for example, stainless steel, nichrome or platinum wire, arranged along the glass tube. When the heater arranged along the glass tube is heated, pre-vaporization formulation in the capillary tube 18 is heated to a temperature sufficient to at least partially volatilize pre-vaporization formulation in the capillary tube 18 .
  • At least two electrical leads 26 are bonded to the metallic capillary tube 18 .
  • one electrical lead 26 is coupled to a first, upstream portion 101 of the capillary tube 18 and a second electrical lead 26 is coupled to a downstream, end portion 102 of the capillary tube 18 .
  • the puff sensor 16 detects a pressure gradient caused by the puffing of the adult vaper, and the control circuitry 11 activates the heater 19 to heat the pre-vaporization formulation located in the reservoir 14 .
  • the pre-vaporization formulation contained within a heated portion of the capillary tube 18 is volatilized and expressed out of the outlet 63 , where the pre-vaporization formulation expands and mixes with air and forms a vapor in mixing chamber 240 .
  • the power supply 12 of example embodiments can include a battery arranged in the second section 72 of the e-vaping device 60 .
  • the power supply 12 is configured to apply voltage across the heater 19 , and the heater 19 volatilizes the pre-vaporization formulation housed in the reservoir 14 .
  • the electrical contacts or connection between the heater 19 and the electrical leads 26 are substantially conductive and temperature resistant while the heater 19 is substantially resistive so that heat generation occurs primarily along the heater 19 and not at the contacts.
  • the power supply or battery 12 may be rechargeable and include circuitry allowing the battery to be chargeable by an external charging device.
  • the circuitry when charged, provides power for a pre-determined number of puffs, after which the circuitry may have to be re-connected to an external charging device.
  • the e-vaping device 60 may include control circuitry which can be on a printed circuit board 11 .
  • the control circuitry 11 may also include a heater activation light 27 that is configured to glow when the heater 19 is activated.
  • the heater activation light 27 comprises at least one LED and is at a distal end 28 of the e-vaping device 60 so that the heater activation light 27 illuminates a cap which takes on the appearance of a burning coal during a puff.
  • the heater activation light 27 can be configured to be visible to the adult vaper.
  • the light 27 may also be configured such that the adult vaper can activate and/or deactivate the light 27 when desired, such that the light 27 would not activate during vaping if desired.
  • the e-vaping device 60 further includes a mouth-end insert 20 having at least two off-axis, diverging outlets 21 .
  • the mouth-end insert 20 includes at least two diverging outlets 21 (e.g., 3 to 8 outlets or more).
  • the outlets 21 of the mouth-end insert 20 are located at ends of off-axis passages 23 and are angled outwardly in relation to the longitudinal direction of the e-vaping device 60 (i.e., divergently).
  • the term “off-axis” denotes an angle to the longitudinal direction of the e-vaping device.
  • the mouth-end insert (or flow guide) 20 may include outlets uniformly distributed around the mouth-end insert 20 so as to substantially uniformly distribute vapor in an adult vaper's mouth during use.
  • the e-vaping device 60 is about the same size as a conventional cigarette. In some embodiments, the e-vaping device 60 may be about 80 mm to about 110 mm long, for example about 80 mm to about 100 mm long and about 7 mm to about 10 mm in diameter.
  • the outer cylindrical housing 22 of the e-vaping device 60 may be formed of or include any suitable material or combination of materials.
  • the outer cylindrical housing 22 is formed at least partially of metal and is part of the electrical circuit connecting the control circuitry 11 , the power supply 12 , the puff sensor 16 and the heater 19 .
  • FIG. 3 is a cross-sectional view of an e-vaping device according to an example embodiment.
  • the e-vaping device 60 can also include a middle section (third section) 73 , which can house the liquid pre-vaporization formulation reservoir 14 and the heater 19 .
  • the middle section 73 can be configured to be fitted with a threaded joint 74 ′ at an upstream end of the first section or cartomizer 70 and a threaded joint 74 at a downstream end of the second section 72 .
  • the first section or cartomizer 70 houses the mouth-end insert 20
  • the second section 72 houses the power supply 12 and the control circuitry 11 that is configured to control the power supply 12 .
  • the first section or cartomizer 70 , the second section 72 and the third section 73 include a common outer cylindrical housing 22 extending in a longitudinal direction along the length of the e-vaping device 60 .
  • the middle section 73 is disposable and the first section or cartomizer 70 and/or second section 72 are reusable.
  • the sections 70 , 72 , 73 can be attached by threaded connections or connectors 74 and 74 ′ whereby the middle section 73 can be replaced when the reservoir 14 is used up.
  • the first section or cartomizer 70 is replaceable so as to avoid the need for cleaning the capillary tube 18 and/or heater 19 .
  • the first section or cartomizer 70 , the second section 72 and the middle section 73 may be integrally formed without threaded connections to form a disposable e-vaping device.
  • the reservoir 14 is a tubular, elongated body formed of or including an elastomeric material so as to be flexible and/or compressible when squeezed.
  • the elastomeric material can be one of silicone, plastic, rubber, latex, and combinations thereof.
  • the reservoir 14 is in fluid communication with a capillary tube 18 so that when squeezed, the reservoir 14 can deliver a volume of a pre-vaporization formulation such as a liquid material to the capillary tube 18 .
  • a pre-vaporization formulation such as a liquid material
  • the power supply 12 is activated upon the application of the manual pressure on the reservoir 14 , and the capillary tube 18 is heated to form a heated section wherein the pre-vaporization formulation is volatilized.
  • the volatilized material expands, mixes with air and forms a vapor.
  • the reservoir 14 includes a valve 40 configured to maintain the liquid pre-vaporization formulation within the reservoir 14 and to open when the reservoir 14 is squeezed and pressure is applied to the reservoir 14 .
  • the valve 40 opens when a critical, minimum pressure is reached so as to avoid inadvertent dispensing pre-vaporization formulation from the reservoir 14 or activating the heater 19 .
  • the pressure required to press the pressure switch 44 is high enough such that accidental heating is avoided. Such arrangement avoids activation of the heater 19 in the absence of pre-vaporization formulation being pumped through the capillary. Once pressure upon the reservoir 14 is relieved, the valve 40 closes and the heated capillary tube 18 discharges any pre-vaporization formulation remaining downstream of the valve 40 .
  • the strength enhancers or additives may include cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • the strength enhancers may also include capsicum , allyl isothiocyanate, piperine, isoeugenol, carvacrol, thymol, menthol, monomenthyl succinate and N-(2-hydroxyethyl)-2,3-dimethyl-2-isopropyl butanamide.
  • the strength enhancers include one or more compounds that activate receptors in the respiratory system of an adult vaper such as the transient receptor potential cation channel, subfamily A, member 1 (TRPA1), the transient receptor potential cation channel subfamily V member 1 (TPRV1), or the nicotinic-acetylcholine receptor agonists in an adult vaper, the receptors becoming part of the particulate phase and are carried in the respiratory tract of the adult vaper with the particulate phase during vaping.
  • TRPA1 transient receptor potential cation channel, subfamily A, member 1
  • TPRV1 transient receptor potential cation channel subfamily V member 1
  • nicotinic-acetylcholine receptor agonists in an adult vaper, the receptors becoming part of the particulate phase and are carried in the respiratory tract of the adult vaper with the particulate phase during vaping.
  • the above compounds as well as others can be found in extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • extracts such as, for example, horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract.
  • the pre-vaporization formulation may include one or more strength enhancers in a composition range of about 0.0001% to about 1%, in concentrations of up to 2%, or in concentrations of more than 2% and less than about 5% when the strength enhancer is a combination of a plurality of strength enhancers.
  • strength enhancers may activate receptors in the respiratory system of an adult vaper.
  • a pre-vaporization formulation such as, for example, a liquid formulation, of an e-vaping device includes a mixture of a vapor former, one or more strength enhancers, nicotine, and/or one or more acids and water.
  • the pre-vaporization formulation optionally includes water.
  • Water may be included in an amount ranging from about 5% by weight based on the weight of the pre-vaporization formulation to about 40% by weight based on the weight of the pre-vaporization formulation. For example, water may be included at about 20% by weight based on the weight of the pre-vaporization formulation.
  • the amount of nicotine in the various formulations may be between about 0.5% and about 1.5% or between about 0.5% and about 2%.
  • the various strength enhancers are discussed above.
  • the acid discussed below includes at least one of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid,
  • a pre-vaporization formulation solution includes about a few ppm or about 0.001% to about 0.1% of a strength enhancer or additive, about 60%-80% of a vapor former (for example, propylene glycol and glycerol in substantially equal concentrations), about 10% to 20% water, about 0.5% to 2% nicotine by weight (NBW), and up to 5% of an acid.
  • a strength enhancer or additive for example, propylene glycol and glycerol in substantially equal concentrations
  • a vapor former for example, propylene glycol and glycerol in substantially equal concentrations
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 1% of a strength enhancer or additive, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, and about 1% to 2% nicotine by weight (NBW), and up to about 3% of an acid.
  • a strength enhancer or additive for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 1.5% of a strength enhancer or additive, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 1.5% nicotine by weight (NBW), and up to about 1% of an acid.
  • a strength enhancer or additive for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 2% of a strength enhancer or additive, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and substantially no acid or about 0.1% of the acid.
  • a strength enhancer or additive for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 2% to about 5% of a combination of a plurality of strength enhancers or additives, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and substantially no acid or about 0.1% of the acid.
  • a vapor former for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 0.1% of one of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and up to 5% of an acid.
  • cinnamaldehyde menthone
  • eugenol zingerone or vanillyacetone
  • gingerol about 60%-80% vapor former (for example, propylene glycol and glycerol)
  • vapor former for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 1% of one or more of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and up to 3% of an acid.
  • cinnamaldehyde menthone
  • eugenol zingerone or vanillyacetone
  • gingerol about 60%-80% vapor former (for example, propylene glycol and glycerol)
  • vapor former for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • a pre-vaporization formulation solution includes about 1.5% of one or more of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and up to 1% of an acid.
  • the pre-vaporization formulation includes about 1.5% of a combination of two or more of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • a pre-vaporization formulation solution includes about 2% of a combination of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and substantially no acid.
  • a pre-vaporization formulation solution includes more than about 2% of more than one of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and substantially no acid.
  • the pre-vaporization formulation includes more than about 2% of a combination of two or more of cinnamaldehyde, menthone, eugenol, zingerone or vanillyacetone, and gingerol.
  • a pre-vaporization formulation solution includes about 0.1% to 2.5% of a combination of horseradish oil, garlic extract, onion oil, black pepper, cayenne pepper, ginger oil, thyme oil, cinnamon bark oil, turmeric, fenugreek, cardamom, rosemary extract, grapefruit oil and andrographis extract, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 15%-20% water, about 0.5% to 2% nicotine by weight (NBW), and an optional amount of acid of up to about 5%.
  • vapor former for example, propylene glycol and glycerol
  • a pre-vaporization formulation solution for a smoke cessation device includes about 0.1% to about 2% of a strength enhancer or additive, about 60%-80% vapor former (for example, propylene glycol and glycerol), about 10%-20% water, about 0.5% to 2% nicotine by weight (NBW), and between about 0.1% to about 5% of an acid.
  • a strength enhancer or additive for example, propylene glycol and glycerol
  • NGW nicotine by weight
  • the acid is operative upon the vapor generated from the pre-vaporization formulation upon operation of the e-vaping device so as to reduce the amount of perceived throat harshness, while the strength enhancer is operative upon the vapor to increase the perceived strength of the vapor.
  • the acid has the capacity to transfer into a vaporized formulation.
  • Liquid to vapor transfer efficiency of an acid is the ratio of the mass fraction of the acid in the vaporized formulation to the mass fraction of the acid in the pre-vaporization formulation.
  • the acid has a pre-vaporization formulation such as a liquid to vapor transfer efficiency of about 50% or greater, for example about 60% or greater.
  • a liquid to vapor transfer efficiency of about 50% or greater, for example about 60% or greater.
  • pyruvic acid, lactic acid, oxalic acid, acetic acid and glycolic acid have a liquid to vapor transfer efficiency of about 50% or greater.
  • the pre-vaporization formulation includes an acid having a liquid to vapor transfer efficiency of about 50% or greater.
  • the pre-vaporization formulation excludes any acid having a liquid to vapor transfer efficiency of about 25% or less.
  • the acid has a boiling point of at least about 100° C., and may be included in the pre-vaporization formulation in an amount sufficient to adjust the pH of the pre-vaporization formulation in the range of about 3 to about 8.
  • the pre-vaporization formulation includes one or more of pyruvic acid, formic acid, oxalic acid, glycolic acid, acetic acid, isovaleric acid, valeric acid, propionic acid, octanoic acid, lactic acid, sorbic acid, malic acid, tartaric acid, succinic acid, citric acid, benzoic acid, oleic acid, aconitic acid, butyric acid, cinnamic acid, decanoic acid, 3,7-dimethyl-6-octenoic acid, 1-glutamic acid, heptanoic acid, hexanoic acid, 3-hexenoic acid, trans-2-hexenoic acid, isobutyric acid, lauric acid, 2-methylbutyric acid, 2-methylvaleric acid, myristic acid, nonanoic acid, palmitic acid, 4-pentenoic acid, phenylacetic acid, 3-phenylpropionic acid, hydro

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Physical Vapour Deposition (AREA)
  • Catching Or Destruction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US14/974,211 2015-12-18 2015-12-18 Strength enhancers and method of achieving strength enhancement in an electronic vapor device Abandoned US20170172204A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US14/974,211 US20170172204A1 (en) 2015-12-18 2015-12-18 Strength enhancers and method of achieving strength enhancement in an electronic vapor device
CA3001780A CA3001780A1 (en) 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device
PCT/EP2016/081469 WO2017103136A1 (en) 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device
RU2018125249A RU2730706C2 (ru) 2015-12-18 2016-12-16 Усилители крепости и способ достижения усиления крепости в устройстве для электронного испарения
EP16822652.0A EP3389420B1 (en) 2015-12-18 2016-12-16 Strength enhancers and method of achieving strength enhancement in an electronic vapor device
JP2018526861A JP2019503660A (ja) 2015-12-18 2016-12-16 強さエンハンサー、および電子ベイパー装置で強さの強化を達成する方法
CN201680068322.7A CN108289496A (zh) 2015-12-18 2016-12-16 强度增强剂和实现电子蒸汽烟装置中的强度增强的方法
ES16822652T ES2749951T3 (es) 2015-12-18 2016-12-16 Potenciadores de intensidad y método para mejorar la intensidad en un dispositivo de vapeo electrónico
IL259200A IL259200B2 (en) 2015-12-18 2016-12-16 Strength amplifiers and a method for achieving strength gain in an electronic humidifier
MX2018006898A MX2018006898A (es) 2015-12-18 2016-12-16 Potenciadores de intensidad y metodo para mejorar la intensidad en un dispositivo de vapeo electronico.
PL16822652T PL3389420T3 (pl) 2015-12-18 2016-12-16 Wzmacniacze mocy i sposoby wzmacniające moc w elektronicznym urządzeniu waporyzującym
KR1020187015306A KR102719796B1 (ko) 2015-12-18 2016-12-16 강도 증강제 및 전자 흡연 장치 내의 강도 증강을 달성하는 방법
JP2022081415A JP2022103338A (ja) 2015-12-18 2022-05-18 強さエンハンサー、および電子ベイパー装置で強さの強化を達成する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/974,211 US20170172204A1 (en) 2015-12-18 2015-12-18 Strength enhancers and method of achieving strength enhancement in an electronic vapor device

Publications (1)

Publication Number Publication Date
US20170172204A1 true US20170172204A1 (en) 2017-06-22

Family

ID=57749910

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/974,211 Abandoned US20170172204A1 (en) 2015-12-18 2015-12-18 Strength enhancers and method of achieving strength enhancement in an electronic vapor device

Country Status (11)

Country Link
US (1) US20170172204A1 (ko)
EP (1) EP3389420B1 (ko)
JP (2) JP2019503660A (ko)
CN (1) CN108289496A (ko)
CA (1) CA3001780A1 (ko)
ES (1) ES2749951T3 (ko)
IL (1) IL259200B2 (ko)
MX (1) MX2018006898A (ko)
PL (1) PL3389420T3 (ko)
RU (1) RU2730706C2 (ko)
WO (1) WO2017103136A1 (ko)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US10834970B2 (en) 2016-12-02 2020-11-17 VMR Products, LLC Combination vaporizer
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
CN114468345A (zh) * 2021-12-28 2022-05-13 四川三联新材料有限公司 一种具有花椒风味的电子烟烟液及其制备方法
CN117481388A (zh) * 2023-11-17 2024-02-02 东莞市吉纯生物技术有限公司 一种抑菌抗炎的口含制品及其制备方法
US12053024B2 (en) 2018-11-05 2024-08-06 Juul Labs, Inc. Cartridges for vaporizer devices
WO2024201300A1 (en) * 2023-03-30 2024-10-03 Rai Strategic Holdings, Inc. Aerosol precursor composition comprising monomenthyl ester
US12114688B2 (en) 2017-10-24 2024-10-15 Rai Strategic Holdings, Inc. Method for formulating aerosol precursor for aerosol delivery device

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7066720B2 (ja) * 2016-12-29 2022-05-13 ジェイティー インターナショナル エス．エイ． たばこムース
CN107343668A (zh) * 2017-08-31 2017-11-14 云南巴菰生物科技有限公司 一种提升香气质感的电子烟油及其制备方法与它的用途
GB201807305D0 (en) * 2018-05-03 2018-06-20 Nicoventures Trading Ltd Vaporisable formulation
GB201817859D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
CN109619655A (zh) * 2019-01-18 2019-04-16 深圳市同信兴投资有限公司 一种复合尼古丁盐及其溶液、其制备方法及应用
FR3093405B1 (fr) * 2019-03-05 2022-07-29 V F P France Compositions de vapotage
US20220304374A1 (en) * 2019-06-25 2022-09-29 Philip Morris Products S.A. Cartridge comprising nicotine and a water-immiscible solvent
FR3110347B1 (fr) 2020-05-20 2022-06-03 V F P France Compositions de vapotage
CN115119957A (zh) * 2022-06-28 2022-09-30 深圳市艾普生物科技有限公司 一种抗氧化电子烟油及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8646461B2 (en) * 2011-12-14 2014-02-11 Sentiens, Llc Device and method for simulating chemosensation of smoking
US20150038576A1 (en) * 2013-08-02 2015-02-05 Sentiens, Llc Compositions and their use for smoking cessation and other treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62175896U (ko) * 1986-04-25 1987-11-09
WO1997007771A1 (fr) * 1995-08-29 1997-03-06 V. Mane Fils S.A. Compositions rafraichissantes
AU6246099A (en) * 1998-09-17 2000-04-03 Wei-Hsin Hou Cigarette filter made from surface activated particulate particles
ES2288701T3 (es) * 2003-11-04 2008-01-16 Firmenich Sa Ingredientes de sabor para preparaciones refrescantes.
US20080038386A1 (en) * 2006-08-02 2008-02-14 Ashok K Moza Use of a liquid cooling sensate to provide a pungent, warming or tingling sensate composition
GB0712308D0 (en) * 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
WO2013164706A1 (en) * 2012-04-30 2013-11-07 Philip Morris Products S.A. Smoking article mouthpiece with cooling agent inclusion complex
US20140261486A1 (en) * 2013-03-12 2014-09-18 R.J. Reynolds Tobacco Company Electronic smoking article having a vapor-enhancing apparatus and associated method
IL297399B2 (en) 2013-05-06 2024-02-01 Juul Labs Inc Nicotine salt formulations for aerosol devices and methods thereof
CN110367592B (zh) * 2013-07-19 2022-12-02 奥驰亚客户服务有限责任公司 电子吸烟器具的液体气溶胶制剂
US9877511B2 (en) * 2013-07-24 2018-01-30 Altria Client Services Llc Electronic smoking article
LU92296B1 (de) * 2013-10-18 2015-04-20 Valeo Lab Gmbh Fl}ssige Zusammensetzung f}r eine elektronische Zigarette
CN113142679A (zh) 2013-12-05 2021-07-23 尤尔实验室有限公司 用于气雾剂装置的尼古丁液体制剂及其方法
KR102402245B1 (ko) * 2014-02-10 2022-05-26 필립모리스 프로덕츠 에스.에이. 히터 조립체를 포함하고 있는 에어로졸 발생 시스템용 카트리지

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8646461B2 (en) * 2011-12-14 2014-02-11 Sentiens, Llc Device and method for simulating chemosensation of smoking
US20150038576A1 (en) * 2013-08-02 2015-02-05 Sentiens, Llc Compositions and their use for smoking cessation and other treatments

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US10667560B2 (en) 2013-12-23 2020-06-02 Juul Labs, Inc. Vaporizer apparatus
US11752283B2 (en) 2013-12-23 2023-09-12 Juul Labs, Inc. Vaporization device systems and methods
US10912331B2 (en) 2013-12-23 2021-02-09 Juul Labs, Inc. Vaporization device systems and methods
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10701975B2 (en) 2013-12-23 2020-07-07 Juul Labs, Inc. Vaporization device systems and methods
US10117466B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10117465B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10058124B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10201190B2 (en) 2013-12-23 2019-02-12 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10264823B2 (en) 2013-12-23 2019-04-23 Juul Labs, Inc. Vaporization device systems and methods
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10070669B2 (en) 2013-12-23 2018-09-11 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD929036S1 (en) 2016-06-16 2021-08-24 Pax Labs, Inc. Vaporizer cartridge and device assembly
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD913583S1 (en) 2016-06-16 2021-03-16 Pax Labs, Inc. Vaporizer device
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10834970B2 (en) 2016-12-02 2020-11-17 VMR Products, LLC Combination vaporizer
USD927061S1 (en) 2017-09-14 2021-08-03 Pax Labs, Inc. Vaporizer cartridge
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US12114688B2 (en) 2017-10-24 2024-10-15 Rai Strategic Holdings, Inc. Method for formulating aerosol precursor for aerosol delivery device
US12053024B2 (en) 2018-11-05 2024-08-06 Juul Labs, Inc. Cartridges for vaporizer devices
CN114468345A (zh) * 2021-12-28 2022-05-13 四川三联新材料有限公司 一种具有花椒风味的电子烟烟液及其制备方法
WO2024201300A1 (en) * 2023-03-30 2024-10-03 Rai Strategic Holdings, Inc. Aerosol precursor composition comprising monomenthyl ester
CN117481388A (zh) * 2023-11-17 2024-02-02 东莞市吉纯生物技术有限公司 一种抑菌抗炎的口含制品及其制备方法

Also Published As

Publication number Publication date
JP2019503660A (ja) 2019-02-14
WO2017103136A1 (en) 2017-06-22
JP2022103338A (ja) 2022-07-07
CA3001780A1 (en) 2017-06-22
IL259200A (en) 2018-07-31
ES2749951T3 (es) 2020-03-24
IL259200B1 (en) 2023-05-01
CN108289496A (zh) 2018-07-17
EP3389420B1 (en) 2019-09-11
KR20180094868A (ko) 2018-08-24
MX2018006898A (es) 2018-09-06
EP3389420A1 (en) 2018-10-24
PL3389420T3 (pl) 2020-06-15
RU2018125249A (ru) 2020-01-20
IL259200B2 (en) 2023-09-01
RU2018125249A3 (ko) 2020-04-14
RU2730706C2 (ru) 2020-08-25

Similar Documents

Publication Publication Date Title
US20170172204A1 (en) Strength enhancers and method of achieving strength enhancement in an electronic vapor device
US10327472B2 (en) Pre-vaporization formulation for controlling acidity in an e-vaping device
RU2706839C2 (ru) Жидкий состав для электронного устройства для парения
US11337453B2 (en) Liquid aerosol formulation of an electronic smoking article
US20150313275A1 (en) Liquid aerosol formulation of an electronic smoking article
JP7258761B2 (ja) ｅベイピング装置の動作中に有機酸を形成するためのプレベイパー製剤
KR102719796B1 (ko) 강도 증강제 및 전자 흡연 장치 내의 강도 증강을 달성하는 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALTRIA CLIENT SERVICES LLC, VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KANE, DAVID;ANDERSON, ADAM;LIPOWICZ, PETER;AND OTHERS;SIGNING DATES FROM 20160225 TO 20160303;REEL/FRAME:037960/0024

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION